Interestingly, two-phase 2a clinical trials reported that pharmacological FGF21 treatment improves liver steatosis in NASH patients (Sanyal et al., 2019; Harrison et al., 2021). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.